Suraksha Diagnostic Limited is the largest integrated diagnostic chain in Eastern India, with a significant presence in West Bengal. Established in 1992, the company has evolved from a single center to a comprehensive network comprising 8 labs (including 4 NABL-accredited labs), 66 diagnostic centers, and 173 collection centers as of December 2025. Suraksha operates on a proven "hub and spoke" model, which enhances operational efficiency and allows for economies of scale. This model features large hub centers equipped with advanced radiology and pathology testing capabilities, which support a network of smaller spoke centers that handle sample collection and basic to intermediate testing.

The company provides a one-stop solution for healthcare needs, offering a diversified service mix that includes pathology (48% of 9M FY26 revenue), radiology (46%), and other services like doctor consultations through its polyclinic chambers (6%). This integrated approach is designed to increase patient footfalls and revenue per patient. Suraksha has built a strong brand with high consumer recall, driven by a commitment to quality, technologically advanced clinical infrastructure, and customer-centric services such as home sample collection and online access to reports. The company is led by an experienced board and management team and is focused on leveraging its dominant position to expand further into the fragmented and underserved markets of Eastern and North-Eastern India.

Official Website: http://www.surakshanet.com/

• Q3 FY26 Performance:

• Total revenue reached ₹783.1 million, a 30.3% increase year-over-year (YoY) from ₹601.1 million in Q3 FY25.

• EBITDA grew 26.1% YoY to ₹237.8 million, though the EBITDA margin saw a slight compression to 30.6% from 31.7% in the prior year's quarter.

• Profit After Tax (PAT) increased by 21.0% YoY to ₹72.4 million. The PAT margin was 9.3%.

• 9M FY26 Performance:

• For the nine months ended December 31, 2025, total revenue was ₹2,313.8 million, a 21.8% increase over the same period last year.

• EBITDA for the 9-month period rose 12.8% YoY to ₹734.0 million. The EBITDA margin was 32.1%, down from 34.8% in 9M FY25, reflecting investments in expansion.

• PAT for 9M FY26 stood at ₹252.4 million, a 6.0% increase YoY.

• Historical Performance (FY23-FY25):

• The company demonstrated strong growth with total revenue increasing at a CAGR of 15.0% from ₹1,936.9 million in FY23 to ₹2,559.4 million in FY25.

• EBITDA showed robust growth with a CAGR of 33.9%, rising from ₹474.5 million in FY23 to ₹850.9 million in FY25.

• PAT grew exceptionally at a CAGR of 126.0% over the same period, from ₹60.7 million to ₹309.8 million.

• Balance Sheet and Cash Flow:

• As of FY25, the company's total assets stood at ₹3,335.2 million with a total equity of ₹2,102.3 million.

• The company generated a strong Net Cash from Operating Activities of ₹633.6 million in FY25.

Suraksha Diagnostic demonstrates strong revenue growth, but recent margin compression reflects the upfront costs of its aggressive expansion strategy.

• Integrated Diagnostic Model: Suraksha is not just a testing center; it offers an integrated one-stop solution. This includes pathology, advanced radiology (MRI, CT scans), and medical consultations via its polyclinic chambers, which house over 1,000 doctors. This model drives higher patient footfalls and revenue diversification.

• Hub and Spoke Operating Model: The company successfully operates a hub and spoke model, particularly in the Greater Kolkata region. Large, well-equipped hub centers process complex tests and support a dense network of spoke centers, maximizing asset utilization and creating significant economies of scale.

• Dominant Regional Presence: Suraksha is the largest diagnostic chain in Eastern India, with 64 of its 66 centers located in West Bengal. This deep penetration in a fragmented market provides a strong competitive advantage and high brand recall.

• First-Mover in Genomics: With the launch of Suraksha Genomics, the company has established a significant first-mover advantage in the high-value genetic and molecular testing segment in Eastern India, positioning itself at the forefront of advanced diagnostics.

The company's unique integrated model, efficient hub-and-spoke network, and regional dominance create a strong competitive moat.

• High Growth Market: The Indian diagnostic industry is projected to grow at a 10-12% CAGR between FY24 and FY28, reaching ₹1,275-1,375 billion. The radiology segment is expected to outpace pathology, growing at an 11-13% CAGR.

• Shift to Organized Players: The market is witnessing a clear shift from standalone labs to organized diagnostic chains. Organized chains are expected to increase their market share from 13-17% in FY20 to 20-24% by FY24, indicating a consolidation trend.

• Eastern India Opportunity: Eastern India is a key strategic market. It has the country's largest share of population but the lowest share of the diagnostics market, indicating it is significantly underserved.

• Favorable Pricing and Low Penetration: The Eastern India market offers premium pricing for diagnostic tests compared to other regions. It also has the lowest number of NABL-accredited labs per million population (0.96 vs. a national average of 1.61), presenting a significant opportunity for quality-focused organized players.

The diagnostic industry is poised for strong growth, with a clear trend towards consolidation that favors organized players like Suraksha, especially in the underserved Eastern Indian market.

• Financial Growth: Revenue grew 30% YoY in Q3 FY26 and 22% for 9M FY26. This growth is primarily attributed to the company's aggressive expansion and increasing patient volumes.

• Operational Expansion: The company has been rapidly expanding its physical footprint. In 9M FY26, 12 new centers were made fully operational, with another 6 under development and planned for a Q4 FY26 launch. The total number of centers grew from 53 in 9M FY25 to 66 in 9M FY26.

• Patient and Test Volume Growth: The number of patients served in 9M FY26 increased to 1.07 million from 0.90 million in the prior year period. Correspondingly, the number of tests performed grew from 4.86 million to 6.18 million.

• Inorganic Growth: In April 2025, Suraksha acquired a 63% stake in Fetomat Wellness Private Limited, a network of fertility and pregnancy care clinics. This strategic move integrates fetal medicine expertise into its existing framework and expands its service offerings.

• New Verticals: The launch of Suraksha Genomics in July 2025 marks an entry into the high-growth advanced genetic testing market, projected to grow from $38.77 billion in 2024 to $186.64 billion by 2035 globally.

Growth is being driven by a multi-pronged strategy of aggressive organic network expansion, strategic acquisitions, and entry into new high-potential service verticals.

• Geographic Expansion: A primary opportunity lies in expanding the company's footprint in its core geography of West Bengal and adjacent, underserved markets in Eastern and North-Eastern India (e.g., Bihar, Assam, Meghalaya) by replicating its successful hub-and-spoke model.

• Inorganic Growth through Acquisitions: The company plans to supplement its organic growth with selective acquisitions of local diagnostic centers that have strong brand recognition and customer bases, accelerating market consolidation.

• Enhancing Service Mix: There is a significant opportunity to increase the share of medical consultation services by setting up more polyclinics within existing centers. This will drive higher footfalls, increase tests per patient, and improve average revenue per patient.

• Technology Integration: Investing in digital technology, AI, and machine learning can enhance diagnostic accuracy, reduce turnaround times, and elevate the overall customer experience, creating a key differentiator.

• B2B and Corporate Partnerships: Strengthening partnerships with B2B and institutional customers presents an opportunity to diversify the revenue mix and increase brand penetration across new customer segments.

Suraksha has clear opportunities to drive future growth by deepening its regional dominance, expanding its service offerings, and leveraging technology.

• Aggressive Expansion Capex: The company is in a heavy investment phase to build out its network. In 9M FY26 alone, 12 new centers were launched, with 6 more planned for Q4 FY26. This indicates significant capital expenditure on infrastructure.

• Investment in New Centers: As of FY25, Capital Work-in-Progress stood at ₹101.0 million, a substantial increase from ₹13.1 million in FY24, reflecting ongoing construction and setup of new diagnostic centers.

• Acquisition-Related Investments: The company made a strategic investment in Fetomat Wellness in April 2025, acquiring a 63% stake. It also invested ₹10.0 million in other financial assets in FY25.

• Historical Capex: Cash flow statements show a consistent investment in assets, with ₹420.2 million spent on the purchase of property, plant, and equipment in FY25.

The company is actively deploying capital towards expanding its physical network and acquiring strategic assets to build future capacity.

• Continued Network Expansion: The immediate plan includes opening 6 more centers in Q4 FY26, comprising hub, spoke, and Public-Private Partnership (PPP) models in locations like Kolkata, Durgapur, and Kharagpur.

• Consolidate Core Markets: The strategy is to set up more hub centers to form new clusters and add spoke centers within existing clusters to deepen penetration and solidify its leading position in West Bengal.

• Expand into Adjacent Geographies: The company will replicate its successful hub-and-spoke and polyclinic models in key locations across Eastern and North-Eastern India to expand its customer base and improve profitability.

• Scale New Ventures: A key focus will be on scaling the newly launched Suraksha Genomics vertical, aiming to become a leader in advanced molecular diagnostics, including prenatal diagnostics, oncology panels, and pharmacogenomics.

• Leverage Technology: Future plans include integrating AI and machine learning to enhance customer experience and diagnostic accuracy, thereby creating a more convenient one-stop solution for patients.

Suraksha's future is focused on disciplined geographic expansion, scaling its high-margin genomics business, and leveraging technology to enhance its service delivery.

• Short-Term Margin Compression: EBITDA margin for 9M FY26 was 32.1%, a compression from 34.8% in 9M FY25. The management commentary explicitly attributes this to the planned pre-operative operating expenses (OPEX) of newly launched centers and those in the pipeline.

• High Profitability of Mature Centers: The underlying business remains highly profitable. Centers older than two years ("mature centers") operate at a robust EBITDA margin of 36-37%. This validates the long-term viability of the company's business model.

• Initial Losses from New Centers: Centers younger than two years are currently operating at a negative EBITDA margin (-12.5% in Q3 FY26). This is expected as new centers require time to ramp up revenue and achieve operational breakeven.

• Efficiency Gap: There is a clear efficiency gap between mature and new centers. In Q3 FY26, a mature center generated an average monthly revenue of ₹4.29 million at a 36.2% EBITDA margin, while new centers are not yet profitable. As new centers mature, they are expected to converge toward the profitability profile of the older centers.

The current margin compression is a planned, short-term outcome of strategic investments for long-term growth, with the core mature business operating at very healthy profitability levels.

• Fragmented Market Structure: The Indian diagnostic industry is highly fragmented. Suraksha competes with three main categories of players: other organized diagnostic chains (both multi-regional and regional), hospital-based laboratories, and a vast number of unorganized standalone labs.

• Gaining Share from Unorganized Players: A key industry trend is the steady shift in market share from standalone labs to organized chains. Organized players are better positioned due to their brand recognition, quality assurance (like NABL accreditation), advanced technology, and wider service menus.

• Regional Leadership: While competing in a broad market, Suraksha's strategy is focused on dominating the Eastern India region, where the penetration of organized chains is low. This provides a distinct advantage over national players who may lack the same depth of network and brand loyalty in this specific geography.

Suraksha operates in a fragmented market but holds a leadership position in its core geography, benefiting from the industry-wide shift towards organized and reliable service providers.

• Execution Risk: The company's aggressive expansion plan, involving the rapid rollout of new centers, carries significant execution risk. Delays or cost overruns could impact financial performance and timelines.

• Short-Term Financial Pressure: The upfront costs associated with new centers are causing a planned compression in EBITDA margins. A slower-than-expected ramp-up in revenue from these new centers could prolong this pressure on profitability.

• Competition: The diagnostic industry is competitive. Increased competition from other organized chains expanding into Eastern India or aggressive pricing from local players could impact market share and pricing power.

• Economic and Market Risks: The business is subject to broader economic risks. A downturn in the Indian economy could affect consumer spending on healthcare and diagnostic services.

The primary risks are centered on the successful execution of its ambitious expansion strategy and the associated short-term impact on profitability.

• Strategic Acquisition of Fetomat: In April 2025, Suraksha acquired a 63% stake in Fetomat Wellness, a network specializing in fertility and pregnancy care. This acquisition enhances Suraksha's service portfolio by integrating fetal medicine expertise and strengthens its position in women's healthcare diagnostics.

• Launch of Suraksha Genomics: The company launched a new vertical, Suraksha Genomics, in July 2025 to offer advanced genetic and molecular testing services. This strategic initiative positions Suraksha in a high-growth, high-value segment of the diagnostics market, focusing on areas like prenatal diagnostics, inherited disease analysis, and oncology.

• Marquee Shareholding: As of December 31, 2025, the company has a diversified shareholding pattern. The Promoter & Promoter Group holds 49.00%, with significant stakes held by Foreign Institutional Investors (FIIs) at 13.46% and Domestic Institutional Investors (DIIs) at 22.56%, indicating strong institutional confidence.

Recent strategic moves into fetal medicine and genomics signal a clear intent to move up the value chain and capture future growth drivers in specialized diagnostics.